RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver diseases and can progress to advanced fibrosis and end-stageliver disease. Thus, intensive research has been performed to develop noninvasive methods for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Currently, no single noninvasive tool covers all of the stages of pathologies and conditions ofNAFLD, and the cost and feasibility of known techniques are also important issues. Blood biomarkers for NAFLD may be useful toselect subjects who need ultrasonography (US) screening for NAFLD, and noninvasive tools for assessing fibrosis may be helpful toexclude the probability of significant fibrosis and to predict advanced fibrosis, thus guiding the decision of whether to perform liverbiopsy in patients with NAFLD. Among various methods, magnetic resonance-based methods have been shown to perform betterthan other methods in assessing steatosis as well as in detecting hepatic fibrosis. Many genetic markers are associated with the development and progression of NAFLD. Further well-designed studies are needed to determine which biomarker panels, imaging studies, genetic marker panels, or combinations thereof perform well for diagnosing NAFLD, differentiating NASH and fibrosis, andfollowing-up NAFLD, respectively.

참고문헌 (Reference)

1 Siddiqui MS, "Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease" 17 : 156-163, 2019

2 Noureddin M, "Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials" 58 : 1930-1940, 2013

3 Nasr P, "Using a 3% proton density fat fraction as a cut-off value increases sensitivity of detection of hepatic steatosis, based on results from histopathology analysis" 153 : 53-55, 2017

4 Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance" 67 : 1560-1599, 2018

5 Mikolasevic I, "Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease: where do we stand?" 22 : 7236-7251, 2016

6 Krawczyk M, "Toward genetic prediction of nonalcoholic fatty liver disease trajectories : PNPLA3 and beyond" 158 : 1865-1880, 2020

7 Kahn HS, "The"lipid accumulation product"performs better than the body mass index for recognizing cardiovascular risk : a population-based comparison" 5 : 26-, 2005

8 Athyros VG, "The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement" 71 : 17-32, 2017

9 Gunn NT, "The use of liver biopsy in nonalcoholic fatty liver disease : when to biopsy and in whom" 22 : 109-119, 2018

10 Thabet K, "The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B" 65 : 1840-1850, 2017